Introduction
============

Selective serotonin reuptake inhibitors are used to treat major depressive disorder and anxiety disorder ([@B18]; [@B1]; [@B17]). Recently, an *in vitro* study showed that selective serotonin reuptake inhibitors seemed to have anti-tumor effects on human hepatocellular carcinoma ([@B25]). A animal study showed that fluoxetine, one of selective serotonin reuptake inhibitors, was not associated with increased incidence of hepatocellular carcinoma in rats and mice ([@B2]). Clinically, a cohort study showed that selective serotonin reuptake inhibitors use was not significantly associated with increased incidence of hepatocellular carcinoma ([@B16]). Furthermore, a case-control study showed that selective serotonin reuptake inhibitors use was significantly associated with decreased odds for hepatocellular carcinoma ([@B9]). Inconsistent results exit on the relationship between selective serotonin reuptake inhibitors use and hepatocellular carcinoma.

Hepatocellular carcinoma was the second leading cause of cancer death in Taiwan in 2016 ([@B49]). In Taiwan, hepatitis B, hepatitis C, heavy alcohol consumption, and diabetes mellitus are associated with increased risk of hepatocellular carcinoma ([@B53]; [@B6]; [@B26]). Without these comorbid conditions, the likelihood of developing hepatocellular carcinoma is low in Taiwan. Therefore, any study exploring the drug effect on chemoprevention of hepatocellular carcinoma in Taiwan should make an adjustment for these comorbid conditions. To clarify this issue, we designed a population-based case-control study to explore whether there is a relationship between selective serotonin reuptake inhibitors use and hepatocellular carcinoma among persons with any one of these comorbid conditions associated with hepatocellular carcinoma.

Materials and Methods {#s1}
=====================

Data Source
-----------

Taiwan is an independent country with more than 23 million citizens ([@B3]; [@B4]; [@B5]; [@B7]; [@B8]; [@B10]; [@B14],[@B15]; [@B19]; [@B20]; [@B21]; [@B47]; [@B48]; [@B51]; [@B56]; [@B36]; [@B39]; [@B54]). We conducted a population-based case-control study using the database of citizens enrolled in the Taiwan National Health Insurance Program. This insurance program began in March 1995 and the enrollment rate has exceeded 99.6% of the entire population of 23 million citizens living in Taiwan in 2015 ([@B50]). The study was approved by the Research Ethics Committee of China Medical University and Hospital in Taiwan (CMUH-104-REC2-115). The details of the program have been written down in previous studies ([@B28]; [@B12]; [@B40]; [@B11]; [@B22]).

Selection of Subjects
---------------------

We identified subjects aged 20 years and more with newly diagnosed hepatocellular carcinoma (International Classification of Diseases, Ninth Revision, Clinical Modification, ICD-9 codes 155, 155.0, and 155.2) from 2000 to 2013 as the cases. The date of subjects being diagnosed with hepatocellular carcinoma was defined as the index date. Subjects without the diagnosis of hepatocellular carcinoma were randomly selected as the controls. Both cases and controls were matched with sex, age (5-year interval), and the year of index date. Subjects who had any other cancer (ICD-9 codes 140-208) before the index date were excluded from the study. The definition of subject selection was adapted from previous studies ([@B27],[@B35]).

Comorbidities Related to Hepatocellular Carcinoma
-------------------------------------------------

Comorbidities which could be related to hepatocellular carcinoma were selected as follows: alcohol-related disease, cardiovascular disease, chronic kidney disease, chronic obstructive pulmonary disease, diabetes mellitus, hyperlipidemia, hypertension, as well as chronic liver disease including cirrhosis, hepatitis B, hepatitis C, and other chronic hepatitis. All comorbidities were diagnosed based on ICD-9 codes. The validity of ICD-9 codes has been discussed in previous studies ([@B23]; [@B29], [@B30],[@B31]; [@B41],[@B42], [@B37],[@B38]; [@B52]; [@B55]; [@B45]; [@B24]).

Measurements of Selective Serotonin Reuptake Inhibitors Use and Other Medications Use
-------------------------------------------------------------------------------------

Prescription histories of selective serotonin reuptake inhibitors and other medications including metformin and statin were collected in the study. Selective serotonin reuptake inhibitors available in Taiwan during 2000--2013 were included as follows: fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, and escitalopram. The definition of medication use was found in previous studies ([@B13]; [@B33],[@B34]; [@B43],[@B44]). That is, ever use of medications was classified as a subject who had at least a prescription of medications studied before the index date. Never use of medications was classified as a subject who never had a prescription of medications studied before the index date.

Statistical Analysis
--------------------

We assessed the differences of the demographic status, selective serotonin reuptake inhibitors use, other medications use, and comorbidities between the cases and the controls by using the Chi-square test for categorized variables. The *t*-test was used to examine the difference of mean age between the cases and the controls. Initially, all variables were included in the univariable logistic regression model. Only those significantly associated with hepatocellular carcinoma in the univariable logistic regression model could be further included in the multivariable logistic regression model. We measured the odds ratio (OR) and the 95% confidence interval (CI) for hepatocellular carcinoma associated with selective serotonin reuptake inhibitors use. All analyses were performed using the SAS statistical software (version 9.2; SAS Institute, Inc., Cary, NC, United States). The results were considered statistically significant when two-tailed *P*-values were less than 0.05.

Results
=======

Characteristics of the Study Population
---------------------------------------

In **Table [1](#T1){ref-type="table"}**, we identified 4901 cases with newly diagnosed hepatocellular carcinoma in 2000--2013 and 19604 controls. Both cases and controls had similar distributions of sex and age. The mean ages (standard deviation) were 62.5 (12.3) years in cases with hepatocellular carcinoma and 62.3 (12.4) years in controls, without statistical significance (*t*-test, *P* = 0.44). The cases with hepatocellular carcinoma were more likely to have a higher proportion of ever use of selective serotonin reuptake inhibitors than the controls (7.57% vs. 6.05%, *P* = 0.001). In addition, the proportions of ever use of metformin, alcohol-related disease, chronic kidney disease, chronic liver disease, chronic obstructive pulmonary disease, diabetes mellitus, and hypertension were higher in the cases than the controls, with statistical significance (*P* \< 0.001 for all).

###### 

Characteristics between cases with hepatocellular carcinoma and controls.

                                                        Cases *N* = 4901   Controls *N* = 19604                    
  ----------------------------------------------------- ------------------ ---------------------- ------- -------- ---------
  Sex                                                                                                              0.99
  Female                                                1351               (27.6)                 5404    (27.6)   
  Male                                                  3550               (72.4)                 14200   (72.4)   
  Age group (years)                                                                                                0.99
  20--39                                                828                (16.9)                 3312    (16.9)   
  40--64                                                1820               (37.1)                 7280    (37.1)   
  65--84                                                2253               (46.0)                 9012    (46.0)   
  Age (years), mean ± standard deviation^†^             62.5 ± 12.3        62.3 ± 12.4            0.44             
  Ever use of selective serotonin reuptake inhibitors   371                (7.57)                 1187    (6.05)   0.001
  Other medications                                                                                                
  Ever use of metformin                                 1173               (23.9)                 2827    (14.4)   \<0.001
  Ever use of statin                                    581                (11.9)                 3646    (18.6)   \<0.001
  Comorbidities before index date                                                                                  
  Alcohol-related disease                               799                (16.3)                 998     (5.09)   \<0.001
  Cardiovascular disease                                1653               (33.7)                 6647    (33.9)   0.81
  Chronic kidney disease                                511                (10.4)                 1295    (6.61)   \<0.001
  Chronic liver disease                                 4110               (83.9)                 3029    (15.5)   \<0.001
  Chronic obstructive pulmonary disease                 911                (18.6)                 3233    (16.5)   \<0.001
  Diabetes mellitus                                     990                (20.2)                 1898    (9.68)   \<0.001
  Hyperlipidemia                                        1137               (23.2)                 5905    (30.1)   \<0.001
  Hypertension                                          2454               (50.1)                 9316    (47.5)   \<0.001

Data are presented as the number of subjects in each group with percentages given in parentheses.

∗

Chi-square test, and

†

t

-test comparing cases with hepatocellular carcinoma and controls.

Association between Selective Serotonin Reuptake Inhibitors Use and Hepatocellular Carcinoma
--------------------------------------------------------------------------------------------

In **Table [2](#T2){ref-type="table"}**, all variables were initially included in the univariable logistic regression model. Only those significantly associated with hepatocellular carcinoma in the univariable logistic regression model could be further included in the multivariable logistic regression model. Therefore, only metformin use, statin use, alcohol-related disease, chronic kidney disease, chronic liver disease, chronic obstructive pulmonary disease, diabetes mellitus, hyperlipidemia, and hypertension could be further included for adjustment. After adjustment for co-variables, the multivariable logistic regression model showed that the adjusted OR of hepatocellular carcinoma was 0.92 for subjects with ever use of selective serotonin reuptake inhibitors (95% CI 0.79, 1.08), comparing with never use. The statistical power of our study to detect a clinically important difference is small (statistical power = 0.24).

###### 

Odds ratio and 95% confidence interval of hepatocellular carcinoma associated with selective serotonin reuptake inhibitors use by logistical regression model.

                                                                                   Crude   Adjusted^†^           
  -------------------------------------------------------------------------------- ------- -------------- ------ --------------
  Ever use of selective serotonin reuptake inhibitors (never use as a reference)   1.27    (1.13, 1.43)   0.92   (0.79, 1.08)

†

Initially, all variables were included in the univariable logistic regression model. Only those significantly associated with hepatocellular carcinoma in the univariable logistic regression model could be further included in the multivariable logistic regression model. Therefore, only metformin use, statin use, alcohol-related disease, chronic kidney disease, chronic liver disease, chronic obstructive pulmonary disease, diabetes mellitus, hyperlipidemia, and hypertension could be further included for adjustment.

Sub-analysis of Association between Selective Serotonin Reuptake Inhibitors Use and Hepatocellular Carcinoma among High Risk Subjects
-------------------------------------------------------------------------------------------------------------------------------------

In **Table [3](#T3){ref-type="table"}**, among subjects with any one of comorbidities including alcohol-related disease, chronic liver disease, and diabetes mellitus, the adjusted OR of hepatocellular carcinoma was 0.89 for subjects with ever use of selective serotonin reuptake inhibitors (95% CI 0.75, 1.06), comparing with never use.

###### 

Association between selective serotonin reuptake inhibitors use and hepatocellular carcinoma among high risk subjects.

  Selective serotonin reuptake inhibitors   Any comorbidity^∗^   Case number/control number   Adjusted OR^†^   (95% CI)
  ----------------------------------------- -------------------- ---------------------------- ---------------- --------------
  Never use                                 Yes                  3922/4479                    1.00             (Reference)
  Ever use                                  Yes                  339/490                      0.89             (0.75, 1.06)

∗

Comorbidities including alcohol-related disease, chronic liver disease, and diabetes mellitus.

†

Adjustment for metformin use, statin use, chronic kidney disease, chronic obstructive pulmonary disease, hyperlipidemia, and hypertension

.

Discussion
==========

In Taiwan, hepatitis B, hepatitis C, heavy alcohol consumption, and diabetes mellitus are associated with increased risk of hepatocellular carcinoma ([@B53]; [@B6]; [@B26]). If a person in Taiwan does not have these comorbid conditions, the likelihood of developing hepatocellular carcinoma is low. To the contrary, if a person in Taiwan has one of these comorbid conditions, the likelihood of developing hepatocellular carcinoma is increased. Thus, any study which hopes to explore the drug effect on chemoprevention of hepatocellular carcinoma in Taiwan should focus on persons with any one of these comorbid conditions, not only focusing on the generalized population who does not have these comorbid conditions. Based on this concept, in this study we found that among subjects with any one of these comorbid conditions including alcohol-related disease, chronic liver disease, and diabetes mellitus, selective serotonin reuptake inhibitors use was not significantly associated with of hepatocellular carcinoma (adjusted OR 0.89, 95% CI 0.75, 1.06, **Table [3](#T3){ref-type="table"}**). This finding is compatible with a cohort study showing that selective serotonin reuptake inhibitors use was not significantly associated with increased incidence of hepatocellular carcinoma ([@B16]). Our finding is not compatible with Chen's study showing that selective serotonin reuptake inhibitors use was significantly associated with decreased odds for hepatocellular carcinoma ([@B9]). In addition, our finding was not compatible with an *in vitro* study showing selective serotonin reuptake inhibitors having anti-tumor effects on human hepatocellular carcinoma ([@B25]). As well-known, only when the result of a study reaches statistically significant, can we need to estimate the statistical power. If the result of a study does not reach statistically significant, the statistical power is usually low. Although the statistical power of our study to detect a clinically important difference is small (statistical power = 0.24), it seems to be accepted. Therefore, inconsistent results exit between the *in vitro* study and the epidemiologic studies. It indicates a future research direction to clarify this issue.

Strengths and Limitations
-------------------------

There are some strengths in this study. Our study focuses on patients with any one of the comorbid conditions associated with hepatocellular carcinoma. The results are well-structured and explained. The readers are more convinced to the results.

There are some limitations in this study. First, due to the limitation of case-control study, a causal-effect relationship cannot be established. Second, due to the inherent limitation of the database used, the status of alcohol consumption is not recorded. Thus, we used alcohol-related disease for analysis. This point was mentioned in previous studies ([@B32]; [@B46]). Third, due to the inherent limitation of the database used, we could not determine whether selective serotonin reuptake inhibitors were used as a mono-therapy for the treatment of depressive disorder or anxiety disorder.

Conclusion
==========

The findings indicate that among persons with any one of the comorbid conditions associated with hepatocellular carcinoma, no significant association can be detected between selective serotonin reuptake inhibitors use and hepatocellular carcinoma.
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